BZYR - BURZYNSKI RESEARCH INSTITUTE INC

0.0203
-0.002   -11.823%

Share volume: 8,218
Last Updated: 03-27-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: 0.03%

PREVIOUS CLOSE
CHG
CHG%
$0.02
0.00
-0.11%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
52%
Profitability 35%
Dept financing 43%
Liquidity 0%
Performance 85%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
-18.80%
3 Months
1.50%
6 Months
-47.68%
1 Year
-63.09%
2 Year
-63.09%
Key data
Stock price
$0.02
P/E Ratio 
0.00
DAY RANGE
$0.02 - $0.02
EPS 
$0.00
52 WEEK RANGE
$0.02 - $0.06
52 WEEK CHANGE
-$63.09
MARKET CAP 
5.823 M
YIELD 
N/A
SHARES OUTSTANDING 
131.448 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$8,218
AVERAGE 30 VOLUME 
$6,144
Company detail
CEO:
Region: US
Website: burzynskiclinic.com
Employees: 0
IPO year: 2011
Issue type:
Market: OTCM
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids.

Recent news